Ocular Hypertension
📧 Sign up to get email alerts when something new happens for Ocular Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-09-08FDA Approved: BIMATOPROST — Original Application (Micro Labs Limited)
FDA approved the original application for BIMATOPROST from Micro Labs Limited, authorizing a generic version of bimatoprost for reducing int…
-
FDA approval · 2020-09-03FDA Approved: TRAVOPROST — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application from Apotex Corp. for Travoprost (ophthalmic) under an ANDA, granting additional regulatory clearanc…
-
FDA approval · 2020-09-01FDA Approved: LATANOPROST — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for LATANOPROST submitted by Mylan Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2020-08-27Clinical Trial Update: Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma [Phase 2]
Phase 2 dose-finding trial comparing latanoprost to a novel glaucoma treatment, with completed status and results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-27Clinical Trial Update: A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension. [Phase 2]
Phase 2 dose-finding trial of PF-03187207 in primary open-angle glaucoma or ocular hypertension completed with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-08-12FDA Approved: BIMATOPROST — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for bimatoprost submitted by Sandoz Inc, authorizing an addition/adjustment to the product's app…
-
CLINICAL_TRIALS trial_result · 2020-08-04Clinical Trial Update: Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6 [Phase 2]
Phase 2 trial assessing safety and efficacy of DE-117 ophthalmic solution administered once daily and twice daily in primary open-angle glau…
-
CLINICAL_TRIALS trial_result · 2020-06-25Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of CKD-351 for primary open angle glaucoma and ocular hypertension.
-
CLINICAL_TRIALS trial_result · 2020-06-04Clinical Trial Update: Dose-Ranging Study of the Bimatoprost Ocular Insert [Phase 2]
Phase 2 dose-ranging study of the bimatoprost ocular insert for open-angle glaucoma and ocular hypertension completed.
-
FDA approval · 2020-06-01FDA Approved: ROCKLATAN — Supplemental Application (Alcon Laboratories, Inc.)
The FDA approved a supplemental application for ROCKLATAN (netarsudil and latanoprost ophthalmic solution) submitted by Alcon Laboratories.
-
FDA approval · 2020-05-28FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION — Original Application (Micro Labs Limited)
FDA approved Micro Labs Limited's generic dorzolamide hydrochloride and timolol maleate ophthalmic solution. It is indicated for reduction o…
-
CLINICAL_TRIALS trial_result · 2020-04-24Clinical Trial Update: Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension [Phase 3]
Phase 3 trial update on the efficacy and safety of bimatoprost sustained-release (SR) for open-angle glaucoma or ocular hypertension has com…
-
FDA approval · 2020-04-03FDA Approved: TIMOLOL MALEATE — Supplemental Application (Pacific Pharma, Inc.)
FDA approved a supplemental application for timolol maleate from Pacific Pharma, Inc. under the ANDA. The action supplements the existing ap…
-
FDA approval · 2020-04-03FDA Approved: TIMOLOL MALEATE — Supplemental Application (Pacific Pharma, Inc.)
The FDA approved a supplemental application for timolol maleate submitted by Pacific Pharma, Inc.
-
FDA label_change · 2020-04-02FDA Approved: TRAVATAN Z — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TRAVATAN Z (travoprost) from Novartis Pharmaceuticals Corporation, resulting in a labeling c…
-
CLINICAL_TRIALS trial_result · 2020-04-02Clinical Trial Update: Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose [Phase 4]
Phase 4 trial comparing Monoprost with Lumigan formulations for safety and efficacy in primary open angle glaucoma and ocular hypertension; …
-
CLINICAL_TRIALS trial_result · 2020-03-30Clinical Trial Update: Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension [Phase 1, Phase 2]
Phase 1/2 trial update on a new ophthalmic formulation of bimatoprost for open-angle glaucoma and ocular hypertension; results have been pos…
-
FDA approval · 2020-03-25FDA Approved: DORZOLAMIDE HYDROCHLORIDE — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for dorzolamide hydrochloride from Sandoz Inc., granting regulatory clearance for changes to thi…
-
FDA approval · 2020-03-04FDA Approved: DURYSTA — Original Application (Allergan, Inc.)
FDA approved DURYSTA (bimatoprost intracameral implant) from Allergan as the original approval for reducing intraocular pressure in adults w…
-
FDA label_change · 2020-02-21FDA Approved: LATANOPROST — Supplemental Application (Bausch & Lomb Incorporated)
FDA approved a supplemental application for latanoprost submitted by Bausch & Lomb Incorporated.
-
FDA approval · 2020-02-19FDA Approved: LATANOPROST — Supplemental Application (Somerset Therapeutics, LLC)
FDA approved a supplemental application for latanoprost submitted by Somerset Therapeutics, LLC.
-
FDA approval · 2020-02-19FDA Approved: LATANOPROST — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for latanoprost from Rising Pharma Holdings, Inc., indicating a supplemental approval for this gener…
-
FDA approval · 2020-02-19FDA Approved: LATANOPROST — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for a generic latanoprost product from Sandoz Inc., enabling its market availability. The approv…
-
FDA approval · 2020-01-27FDA Approved: TRAVOPROST — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application from Apotex Corp. for a generic travoprost product.
-
FDA approval · 2020-01-21FDA Approved: BIMATOPROST — Original Application (Alembic Pharmaceuticals Limited)
FDA approved the original application for bimatoprost (generic) by Alembic Pharmaceuticals Limited.